🔗 Share this article

Given that the US continues making unprecedented adjustments to its vaccination recommendations, a particular individual appears in a surprising turn: Dr. Tracy Beth Høeg, a US-based physician and epidemiologist who first made her name by casting doubt on COVID-19 vaccinations in the pandemic and has focused upon possible fatalities following COVID-19 immunization in her short position at the US Food and Drug Administration (FDA).

Scheduled Shifts to Childhood Immunization Schedule

Health officials planned to unveil sweeping revisions to the childhood vaccine schedule recently, synchronizing the US with the Danish vaccine program, it is understood – a substantial departure that would place the US at odds with much of the global community with insufficient data for public health gain. The announcement has been delayed until the coming year.

Rather than the top vaccines chief, Høeg is scheduled to address the audience at the event. She was recently named temporary leader of the FDA’s CDER, the fifth person to head the office this year.

Consolidating Power at the FDA

This interim role might represent a tighter collaboration between the pharmaceutical and vaccine divisions as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it signals a increased emphasis upon rolling back already-approved immunizations at the FDA.

The new acting director has frequently advocated for halting some pediatric immunization guidelines in the US in order to be more in line with Denmark's approach, a nation with comprehensive healthcare and a citizenry about the size of the state of Wisconsin.

In her initial statements, she has persisted in emphasizing on vaccination policy – traditionally the purview of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Concerns Over Background

Dr. Høeg has no obvious background in pharmaceutical research, approval processes or leadership, which has been standard for former heads of the biologics center. She has served at the FDA as a senior adviser to the commissioner and CBER since March.

“She doesn’t seem to have the necessary background” for overseeing the pharmaceutical oversight division, said Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in running a large organization. She has no expertise in industry regulation.”

Previous commissioners of the center would “understand legal statutes and the research of drug development”, noted Janet Woodcock. “Clearly, she lacks the kind of background that former directors who ran CBER have had.”

This division has an immense range of responsibilities at the FDA, Woodcock stated.

“Many people just zeroes in on the innovative therapies, but the generic drug division clears numerous generic drugs. There is also a biosimilars division, over-the-counter program and other areas, and every single one must be looked after,” she noted. “The thing you neglect, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a substantial administrative aspect to the job, which oversees more than 5,000 staff members. “It’s a enormous administrative position, if you execute it properly,” Woodcock said.

Official Statement and Controversial Policies

When asked about questions about Høeg’s credentials and whether this appointment signifies increased cooperation among regulatory chiefs on vaccines, a representative responded that the “questions stem from incorrect presumptions”.

“Her resume matches the duties of her position,” the official explained, noting the months Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and vaccine surveillance”.

As acting director, Høeg takes over the commissioner’s new expedited review system, a contentious one-day drug-approval program that apparently troubled her former heads. “By what process are these drugs being selected for this voucher program? Who takes the calls?” Dr. Howard asked. “There is a lot of lack of transparency happening at the FDA right now.”

Broadly speaking, he stated, “the Food and Drug Administration looks to be trending towards less stringent rules of all drugs, aside from immunizations.”

Established Past Work on Immunizations

Concerning immunizations, Høeg has a more documented, if troubling, history, some experts have noted. She authored a research paper using non-validated volunteer-provided data to assess the incidence of heart inflammation after COVID-19 vaccination. She consulted for the Florida top health official Dr. Joseph Ladapo, who reportedly have altered data to imply Covid vaccines are riskier than they are.

Among her “policy goals” for the new government encompassed changing guidelines for novel immunizations and ending “optional” vaccines, she remarked following the vote on a audio program. At the FDA, Høeg has according to sources floated the idea of preventing adolescent males from receiving COVID-19 vaccinations.

“She’s an all-around true believer who commences with her preconceived notions and tailors the evidence to accommodate the data in a highly misleading, fraudulent way,” Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of other skeptics, {like|